Exciting advances in cancer treatment offer reasons for optimism in the field of bio-medicine. Innovative therapies like checkpoint inhibitors, Antibody Drug Conjugates (ADC), bi (and multi) specifics, CAR-T therapies, and cancer vaccines have shown promising results, sparking a revolution in the fight against cancer. The future of cancer therapeutics looks brighter than ever, and Vantage is thrilled to be part of this transformative journey. Together with our collaborators, we are dedicated to pushing the boundaries of scientific understanding and making a tangible difference in patients’ lives.
Beyond the single average tumor: Understanding IO combinations using a clinical QSP model that incorporates heterogeneity in patient response.
Lesion-level heterogeneity of radiologic progression in patients treated with pembrolizumab.
Incorporating lesion-to-lesion heterogeneity into early oncology decision making.